This study is being carried out to learn more about administration of xaluritamig in people with high-risk biochemical recurrence (BCR) or sometimes referred to as nonmetastatic castration-sensitive prostate cancer (nmCSPC) after receiving definitive (primary) treatment.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Young Whang
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Prostate, Phase 1 Trials (all cancers))
Rare Diseases
Men's Health
24-1870
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
